This is a working overview of IGF-1 marker, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-12-11. Anything still debated is marked as such rather than presented as settled.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.
Questions remain about how much of the observed fat reduction reflects direct GHRH-receptor signaling versus the downstream growth hormone and IGF-1 surge. It is also unclear whether the compound produces meaningful benefit in populations without lipodystrophy, since trials in cognitive impairment did not reach their stated goals. Long-term effects on glucose metabolism and on cardiovascular outcomes are not fully characterized. Published work generally describes effects on surrogate markers rather than on hard clinical endpoints, and independent replication of some findings is limited.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C221H366N72O67S | Reflects a 44-residue peptide with one N-terminal modification |
| Approximate molecular weight | 5136 Da | Sequence length and single acyl group determine the mass |
| Appearance | White to off-white lyophilized powder | Typical form of a purified synthetic peptide |
| Solubility class | Soluble in water and aqueous buffer | Peptide backbone favors aqueous dissolution |
| Common synonyms | GHRH(1-44) analogue; Egrifta | Descriptive name and approved brand name |
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
特沙莫瑞林的检测通常依赖反相高效液相色谱和质谱联用。反相色谱可分离肽主峰与缺失序列、氧化产物等杂质，质谱则提供精确质量以确认身份。对于复杂基质中的定量，常采用液相色谱-串联质谱，并配合固相萃取或蛋白沉淀。生物样品中的肽易降解，因此采集和处理条件会影响结果。
稳定性研究通常考察温度、光照、湿度和 pH 对肽链的影响。冻干粉在低温避光条件下较为稳定，复溶后则需控制保存时间并避免反复冻融。肽类可能发生氧化、脱酰胺、水解和聚集，这些变化会改变色谱纯度。强制降解实验用于识别主要降解途径并验证分析方法的专属性。
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
冻干粉末一般在 -20°C 或更低温度、干燥避光条件下保存，可维持较长时间的稳定。复溶后稳定性明显下降，溶液中的肽链易发生水解、氧化与聚集，通常需冷藏并在短期内用完。反复冻融会加速聚集与降解，建议分装后单次使用。缓冲体系的 pH 与离子强度同样影响聚集速率，需要按具体实验条件验证。
研究用与临床用材料的标准并不相同。质量控制通常覆盖纯度、残留溶剂、反离子含量、微生物限度与内毒素水平，各项均有对应检测方法。随货文件应包含批号、检测项目、方法与结果，使数据可以追溯。核验时应关注纯度是否按主峰面积计算、杂质是否已定性、方法是否经过验证，这些信息决定结果能否被外部重复。
==== Extrusion-based printing ingredients ==== Common ingredients used in extrusion-based printing are inherently soft enough to extrude from a syringe/printhead and possess a high enough viscosity to retain a shape. In certain cases, powdered ingredients (protein, sugar, etc.) are added to increase viscosity, e.g. adding flour to water creates a paste that can be printed. Inherently soft materials include:
Neanderthals collected non-functional, uniquely-shaped objects, namely shells, fossils, and gems. It is unclear if these objects were simply picked up for their aesthetic qualities, or if some symbolic significance was applied to them. Some shells may have been painted. Gibraltarian palaeoanthropologists Clive and Geraldine Finlayson suggested that Neanderthals used various bird parts as artistic media, especially black feathers. A 2020 study found evidence of a 3-ply cord fragment made from conifer inner-bark fibres at Abri du Maras, France, which can be used to knit light items, such as strings for hanging beads. 115,000-year-old perforated shell beads from Cueva Antón were possibly strung together to make a necklace. There are several instances of nondescript engravings and scratches on flints, bones, pebbles, and stone slabs — as of 2014, 63 purported engravings have been reported from 27 different European and Middle Eastern Lower-to-Middle Palaeolithic sites. It is debated if these were made with symbolic intent. Neanderthals may have produced finger flutings on the walls of La Roche-Cotard over 57,000 years ago. Neanderthals used ochre, a clay earth pigment. It is unclear if this constitutes evidence of artmaking because, while modern humans have used red ochre for decorative or symbolic colouration, they have also used ochre as medicine, hide tanning agent, food preservative, and insect repellent.
Jollibee is a Filipino fast-food restaurant chain and the flagship brand of Jollibee Foods Corporation (JFC). Established in 1978 by Tony Tan Caktiong, it is the Philippines' top fast-food restaurant and is among the world's fastest-growing restaurant chains, having expanded its international presence almost sixfold from 2014 to 2024. As of January 2024, there were over 1,668 Jollibee fast-food restaurants, including more than 400 outside the Philippines, operating in 17 countries including Canada, Hong Kong, Macau, Malaysia, Singapore, the United Kingdom, the United States, and Vietnam, as well as across the Middle East. Jollibee is best known for its Chickenjoy fried chicken.
Sources: en.wikipedia.org
=== Groupings and organizations === Lucha Libre AAA Worldwide, a Mexican wrestling promotion Asian Athletics Association, the continental athletics authority in Asia Amateur Athletic Association of England, the Athletic Association in England Arkansas Activities Association, for high school sports Montreal AAA, an amateur athletic association Triple-A (baseball), a North American Minor League Baseball classification level Senior ice hockey § Senior AAA hockey leagues
The 1980 Familia/323 was the first front-engine, front-wheel-drive vehicle from Mazda since the R130. This generation of 323 was Wheels magazine's car of the year for 1980. The existing station wagon version, simply a facelifted version of the previous rear-drive model (fitted with the square headlights and grille from the new model), was sold in parallel with the BD. The wagon was available with either three or five doors and was equipped either with the old 1272 cc TC engine or the 1415 cc UC. The 1.4 was replaced from 1983 with the newly developed 1490 cc E5 engine. The TC 1.3 produces 60 PS (44 kW) while the larger versions offer 70 PS (51 kW). By 1985, the old 1.3 was replaced by the 1296 cc E3 engine with 68 PS (50 kW); it was only available with the three-door station wagon body.
== Use in cancer therapy == KLH is being tested in a variety of cancer vaccines, including non-Hodgkin's lymphoma, cutaneous melanoma, breast and bladder cancer. These vaccines contain specific tumor-associated antigens conjugated to KLH to stimulate anti-tumor immune responses which can destroy tumor cells. The rapidly growing interest in therapeutic vaccines (i.e. active immunotherapies) for cancer and the documented efficacy of KLH as a superior carrier protein for cancer vaccines are creating a significant biopharmaceutical market for KLH formulations. Assays to monitor humoral immune responses against KLH in human serum have been developed to facilitate optimal use of biomedical KLH applications.
Sources: en.wikipedia.org
It shares the 44-residue sequence of human GHRH but carries an added trans-3-hexenoyl group at its N-terminus. That addition does not occur in the natural hormone and serves mainly to resist enzymatic breakdown. The receptor target and signaling pathway remain the same.
It binds the growth hormone-releasing hormone receptor on anterior pituitary cells. Activation of that receptor promotes synthesis and release of growth hormone. The effect propagates through the growth hormone and insulin-like growth factor 1 axis.
Native GHRH is cleared quickly by peptidases, which limits how long it can stimulate its receptor. The added group hinders one of the primary cleavage enzymes. The practical consequence is a longer period of receptor activity per dose.
It acts upstream at the pituitary receptor and depends on functioning somatotroph cells to produce any effect. Growth hormone injections bypass that step and deliver the hormone directly. The pharmacokinetic profiles and the resulting feedback on the body's own secretion therefore differ.